Case Report

Herpes Zoster in an Immunocompetent Child without a History of Varicella

Bing-Shiau Shang1,2, Cheng-Jui Jamie Hung2 and Ko-Huang Lue1,2,*

Citation: Shang, B.-S.; Hung, C.-J.J.; Lue, K.-H. Herpes Zoster in an Immunocompetent Child without a History of Varicella. Pediatr. Rep. 2021, 13, 162–167. https://doi.org/10.3390/pediatric13020022

Abstract: Herpes zoster is a relatively rare infectious disease in the pediatric population, as compared with adults, which is due to the reactivation of latent Varicella–Zoster virus. We report a 7-year-old child without any history of varicella, who first experienced skin pain and later presented skin lesions in dermatomal distribution. Finally, the patient was diagnosed with herpes zoster. We aim to emphasize that herpes zoster could occur in immunocompetent children and may be due to the reactivation of the vaccine strain or previous subclinical infection.

Keywords: varicella; herpes zoster; vaccine; pediatric; immunocompetent

1. Introduction

Herpes zoster (HZ), also known as shingles, is a rather uncommon disease in pediatrics which is caused by the reactivation of the latent Varicella–Zoster virus (VZV) [1]. Despite the fact that most patients with HZ have a medical history of varicella, or chickenpox (the manifestation of the primary infection of VZV), there is a group of pediatric populations that has HZ without any record of varicella (infection). Meanwhile, as live attenuated varicella vaccine is routinely administered in many countries worldwide, there are reports stating that HZ has appeared in immunocompetent children after varicella vaccination [2]. We herein report a case of a child of HZ, who received live attenuated varicella vaccine at 12 months old and had no history of varicella.

2. Case Report

This was a 7-year-7-month-old immunocompetent boy with no past history of varicella, or chickenpox, or any other systemic diseases. He was born at a gestational age of 36 weeks via Caesarean section (C-section), due to previous C-section with a maternal history of Gravida 3 Para 3. He received the varicella vaccine, when he was 1 year old which was scheduled in the routine childhood vaccination program. The patient was brought to our emergency department on October 4, 2020 due to multiple vesicles and erythematous rashes over his right buttock and right lower leg after a three-day history of severe burning pain and tenderness, especially during the night, in his right leg. He was hemodynamically stable and had no fever or any neurologic abnormality. Based on the appearance of the patient’s cutaneous lesions, the patient was admitted to our pediatric ward on the same day.

Upon admission, the physical examination revealed numerous fine vesicles on an erythematous base, which distributed approximately around L3 and L4 dermatomes (Figure 1a,b). We noted an antalgic gait, and the patient experienced extensive pain in his right leg. Blood laboratory examinations indicated no leukopenia, leukocytosis or an elevated C-reactive protein (CRP) level. Serologic screening for VZV antibodies (Ab) was also arranged which showed a positive result of VZV IgG Ab and a gray zone result of VZV IgM Ab.
Figure 1. (a,b) Multiple fine vesicles with erythematous bases distributed around right L3 and L4 dermatomes.

Intravenous infusion of acyclovir 10 mg/kg/dose every 8 h and neurologic pain control with oral gabapentin 10 mg/kg/day every 8 h and ibuprofen 15 mg/kg/day every 6 h were prescribed on the first day of the admission. Though more clusters of vesicles appeared on the second and the third admission day, we kept the antiviral treatment throughout the entire clinical course. However, since the patient still complained about persistent burning pain, tightness in the anterior part of his right thigh, we replaced gabapentin with oral pregabalin. The patient also complained of some itching sensation over the vesicular lesions. After the fourth day of admission, the vesicular lesions gradually became dryer, darker and more crusted; no new skin lesions were observed. On 15 October, the twelfth admission day, the patient was discharged with the final diagnosis of herpes zoster. The patient visited our out-patient department for follow-up three weeks after he was discharged, and he no longer felt any pain in his right leg so that postherpetic neuralgia (PHN) was ruled out.

3. Discussion

Since the introduction of the live attenuated varicella vaccine, also known as the Oka vaccine, the incidence of herpes zoster (HZ) in children has declined from 20–63/100,000 to 14/100,000 person-years [3,4]. It is known that HZ in children is rare, in which most patients diagnosed with HZ are immunocompromised or under pharmaceutical treatment with immunosuppressive drugs [5]. On the other hand, while the reactivation of latent VZV, causing HZ, is more common in adults than in pediatric patients, their respective symptoms have slight differences. Whereas pain in dermatomal distribution is mostly complained about by adults with HZ, itching, followed by pain, fever, and weakness, is the most common symptom in children with HZ [6].

Clinical manifestations of HZ in immunocompetent children have been reported. We reviewed 27 previous reports in literature, which comprised 39 immunocompetent children with HZ, all of which were related to a history of either varicella or varicella vaccination (Table 1) [7–33]. In these 39 reported cases, there were 23 male patients and 15 female patients, while one case report did not reveal the sex of the patient. The age of acquiring HZ ranged from 1 year 3 months to 16 years old. Whereas six patients had no history of varicella vaccination, the interval between varicella vaccination and the presentation of HZ varied from 56 days to nearly 9 years. The affected cutaneous region with HZ presentation included various dermatomes, including cervical, thoracic, lumbar, sacral, and trigeminal involvement. There was no distinct connection between the vaccine injection site and the cutaneous lesions of HZ. However, a retrospective study, conducted by Aktas et al., demonstrated that HZ in children younger than 10 years old was more frequently involved with cervical, trigeminal, and sacral dermatomes, while HZ in older children showed a tendency to present thoracic or lumbar involvement [6].
Table 1. Previous Literature of Herpes Zoster in Pediatric Patients.

| Reference                  | Age at Vaccination | Age at \( V_{ZV} \) | Varicella History | Interval between Vaccination and HZ | Dermatomes/Regions with Lesions | VZV Strain | IgM | IgG |
|----------------------------|-------------------|----------------------|-------------------|-----------------------------------|---------------------------------|------------|-----|-----|
| Na, G. Y. et al. (1997)    | 4 y 10 m          | M                    | 2 y               | No                               | R't S3                          | Wild type  | -   | +   |
|                            | 3 y 1 m           | F                    | 1 y 5 m           | No                               | 1 y 8 m                         | L't S3-4    | -   | +   |
|                            | 5 y 5 m           | M                    | 3 y 5 m           | No                               | 2 y                             | R't T2      | -   | ND  |
|                            | 2 y 6 m           | F                    | 1 y               | No                               | 1 y 6 m                         | L't T10     | ND  | +   |
|                            | 3 y 9 m           | F                    | 2 y 5 m           | No                               | 1 y 3 m                         | R't L3-4    | ND  | +   |
|                            | 4 y 2 m           | M                    | 2 y 4 m           | No                               | 1 y 10 m                        | R't S1-2    | ND  | +   |
| Liang, M. G. et al. (1998) | 1 y 7 m           | F                    | 1 y 3 m           | Yes (7 m)                        | 4 m                             | L't C6-7    | ND  | ND  |
| Kohl, S. et al. (1999)     | 6 y               | M                    | 6 y               | No                               | 12 d                            | L't T2      | Wild type | ND  |
| Uebe, B. et al. (2002)     | 2 y 3 m           | F                    | 11 m              | No; contact history with her sister with varicella | 1 y 4 m | R't C6-C8 | Vaccine | -   | +   |
| Feder, H. M. et al. (2004) | 6 y               | F                    | N/A               | Yes (3 m)                        | N/A                             | R't V2-3    | ND  | ND  |
|                            | 3 y               | F                    | N/A               | Yes (6 m)                        | N/A                             | L't L1-2    | ND  | ND  |
|                            | 8 y               | F                    | N/A               | Yes (7 y)                        | N/A                             | R't T6      | ND  | ND  |
|                            | 3 y               | M                    | 1 y               | Yes (6 m)                        | 2 y                             | L't V1      | ND  | ND  |
|                            | 5 y               | F                    | 1 y 3 m           | N/A                             | 3 y 9 m                         | L't L2      | Wild type | ND  |
| Ota, K. et al. (2008)      | 2 y 4 m           | M                    | 1 y 1 m           | N/A                             | 1 y 3 m                         | L't chest and upper limb | Vaccine | ND  | +   |
| Levin, M. J. et al. (2008) | 8 y               | M                    | 1 y               | No                               | 7 y                             | R't shoulder and meningoitis | Vaccine (skin and CSF) | +   | +   |
| Iyer, S. et al. (2009)     | 9 y               | M                    | 1 y               | No                               | 8 y                             | L't C5-6 & meningoitis | Vaccine (Skin and CSF) | ND  | ND  |
| Choularias G. et al. (2010)| 3 y 6 m           | F                    | 1 y 8 m           | No; contact history at 1 y 3 m   | 1 y 10 m                        | R't V1 and encephalitis | Vaccine (CSF) | ND  | ND  |
| Han, J. Y. et al. (2011)   | 7 y               | M                    | 1 y               | No                               | 6 y                             | R't arm and meningoitis | Vaccine (Skin and CSF) | ND  | ND  |
| Iwaski, S. et al. (2016)   | 2 y               | F                    | 1 y 5 m           | No                               | 7 m                             | L't V1-2    | Vaccine | +   | +   |
| Dreyer, S. et al. (2017)   | 3 y               | M                    | 1 y               | N/A                             | 2 y                             | R't L2      | Vaccine | ND  | ND  |
|                            | 2 y               | F                    | 1 y               | No                               | 1 y                             | L't L4      | Vaccine | ND  | ND  |
| Moodley, A. et al. (2018)  | 3 y 3 m           | M                    | 1 y 8 m           | No                               | 1 y 7 m                         | L't L4-S1   | Wild type variant of vaccine | ND  | ND  |
|                            | 1 y 8 m           | M                    | 1 y 1 m           | No                               | 7 m                             | R't L3      | ND  | +   | +   |
|                            | 3 y 6 m           | M                    | 1 y               | No                               | 2 y 6 m                         | R't thigh   | N/A  | N/A |
| Pelekouda, E. et al. (2019)| 4 y               | F                    | 1 y 3 m           | No                               | 2 y 9 m                         | R't C4-5 & T1 | ND  | -   | ND  |
| Yasuda, R. et al. (2019)   | 11 y              | F                    | N/A               | Yes (2 y)                        | N/A                             | L't chest and meningoitis | ND  | -   | +   |
| Harrington, W. E. et al. (2019)| 14 y          | M                    | 1 y 4 y           | No                               | ?                               | L't L1-2 and meningoitis | Vaccine (Skin and CSF) | ND  | ND  |

The references were listed in chronological order. Abbreviations: y = year, m = month, d = day; F = female, M = male; ND = not done in the reported case; N/A = information was not available. The question mark (?) indicates the reported case received more than one dose of varicella vaccine so that the interval between vaccination and HZ was unclear. The symbol “+” indicates positive finding, and the symbol “−” indicates negative finding.
VZV reactivation in children 

HZ is basically diagnosed alongside the clinical presentation and is likely to be derived from the reactivation of either wild type or vaccine strain in immunocompetent children. Some previous cases also performed virology screening that wild-type VZV was identified in six patients and vaccine strain was found in 11 patients, which indicates that varicella vaccine has the potential for causing not only latent infection, but also reactivation. Meanwhile, it was reported that five patients were infected with wild-type VZV without previous exposure to varicella or HZ or any other contact history. Thus, HZ in children may also arise from subclinical infection of VZV \[7,9,11\]. Additionally, despite clustered vesicular lesions in dermatomal distribution being the most common symptom of HZ in children, previous reports also include cases of central nervous system (CNS) infection, in which either wild type or vaccine strain was found in the virology screening for the cerebrospinal fluid (CSF) and further led to meningitis or encephalitis \[13,16,18,19,34\]. It is suggested that both wild type and vaccine strain VZV reactivation, can result in severe complications, especially CNS involvement.

Laboratory examination has not been identified as a necessary process for the diagnosis or treatment of HZ \[1\]. Therefore, in the reviewed articles, VZV-specific IgM tests were performed in 14 cases and positive results of three cases; while VZV-specific IgG test were performed in 13 cases and positive results of all cases. Specific IgM was positive in three cases, two of which were caused by the vaccine strain \[7,10,13,22,27,29,31,32\]. In fact, Kangro et al. and Min et al. suggested HZ would show an IgM-positive result \[35,36\]. Min et al. also found that the IgM level usually peaked around the 6th to 10th day after the cutaneous lesions developed and could persist up to 10 weeks \[36\]. Nevertheless, their studies were not designed specifically for the pediatric population, whose immune response to viral infection is not completely identical to adults. There has been no previous literature discussing the positive duration of IgM in children with HZ particularly either.

Our patient was a 7-year-old boy with HZ involvement around right L3 and L4 dermatomes, which does not correspond with the previous finding that patients under 10 years old are more likely to present HZ in cervical, sacral, and trigeminal dermatomes \[6\]. The serologic test of our patient showed a positive-IgG result and a gray zone (1.01) result of IgM (<0.8 as negative, >1.1 as positive). We supposed the slight increase of IgM level was due to the unreliability of the currently available IgM detection technique, or the early examination of IgM, level of which usually rises on the 6th to 10th day after the appearance of vesicular lesions \[36\]. As he received a dose of varicella vaccine at 1 year old and denied a history of varicella, it was suspected that the HZ was caused by subclinical infection or vaccine strain VZV. Yet due to personal reasons, the patient’s family opposed the arrangement of confirmatory laboratory examination to identify the strain of the VZV infection, which consequently becomes a limitation of the report.

Furthermore, certain gene mutations may be susceptible to specific pathogen infections or activations, including VZV. Korholz et al. had reported a dominant inherited IFNγR1 deficiency in a family \[37\]. The affected patient and one of his sons had recurrent and severe infections (pneumonia, meningoencephalitis, shingles) of VZV, HSV; while another affected son remained clinically healthy. Droman et al. demonstrated that a patient with IFNγR1 deficiency had over 70% of mycobacterial infection from environmental or BCG-vaccine in both dominant and recessive type, with 100% of BCG vaccine-related mycobacteria disease in recessive inherited type \[38\]. Our patient denied having any complications after BCG vaccination at 5 months old (routine vaccination program in Taiwan). However, in countries without a routine BCG vaccination, clinics should be alert to certain immunodeficiency even if the patient was previously healthy.

As both wild type and vaccine strain can contribute to the reactivation of latent VZV, HZ should be considered when a pediatric patient presents vesicular lesions in dermatomal distribution, even without a history of varicella or any contact history. Moreover, since HZ can cause various complications, including CNS infection, physicians should keep it in mind when approaching patients with encephalitis or meningitis. Future studies regarding the positive duration of VZV IgM and IgG levels with a focus on the pediatric
population in particular may also be helpful to ascertain the effectiveness and reliability of the serologic test.

Author Contributions: Conception and design, K.-H.L.; drafting the article, B.-S.S. and C.-J.J.H.; revising the article critically for important intellectual content, B.-S.S.; final approval of the version to be published, K.-H.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to thank the patient and the family for their active participation in publishing this case report. All figures were taken or recorded with the patient’s agreement. Consent of the patient was also obtained for publication of this case report from the family.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kliegman, R.M. Nelson Textbook of Pediatrics. 21st ed.; Elsevier: Philadelphia, MO, USA, 2019.
2. Chun, C.; Weinmann, S.; Riedlinger, K.; Mullooly, J.P.; Houston, H.; Schmid, D.S.; Seward, J.F. Laboratory characteristics of suspected herpes zoster in vaccinated children. Pediatr. Infect. Dis. J. 2011, 30, 719–721. [CrossRef] [PubMed]
3. Guess, H.A.; Broughton, D.D.; Melton, L.J.; 3rd; Kurland, L.T. Epidemiology of herpes zoster in children and adolescents: A population-based study. Pediatrics 1985, 76, 512–517. [PubMed]
4. Leung, A.K.; Robson, W.L.; Leong, A.G. Herpes zoster in childhood. J. Pediatr. Health Care 2006, 20, 300–303. [CrossRef] [PubMed]
5. Lin, H.C.; Chao, Y.H.; Wu, K.H.; Yen, T.Y.; Hsu, Y.L.; Hsieh, T.H.; Wei, H.M.; Wu, J.L.; Muo, C.H.; Hwang, K.P.; et al. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study. Medicine 2016, 95, e4037. [CrossRef] [PubMed]
6. Aktas, H.; Erdal, S.A.; Guvenc, U. Herpes Zoster in children: Evaluation of the sixty cases. Dermatol. Ther. 2019, 32, e13087. [CrossRef]
7. Na, G.Y. Herpes zoster in three healthy children immunized with varicella vaccine (Oka/Biken); the causative virus differed from vaccine strain on PCR analysis of the IV variable region (R5) and of a PstI-site region. Br. J. Dermatol. 1997, 137, 253–258.
8. Liang, M.G.; Heidelberg, K.A.; Jacobson, R.M.; McEvoy, M.T. Herpes zoster after varicella immunization. J. Am. Acad. Dermatol. 1998, 38, 761–763. [CrossRef]
9. Kohl, S.; Rapp, J.; La Russa, P.; Gershon, A.A.; Steinberg, S.P. Natural varicella-zoster virus reactivation shortly after varicella immunization in a child. Pediatr. Infect Dis. J. 1999, 18, 1112–1113. [CrossRef]
10. Uebe, B.; Sauerbrei, A.; Burdach, S.; Honeff, G. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur. J. Pediatr. 2002, 161, 442–444. [CrossRef]
11. Feder, H.M., Jr; Hoss, D.M. Herpes zoster in otherwise healthy children. Pediatr. Infect. Dis. J. 2004, 451–457, 458–560. [CrossRef]
12. Binder, N.R.; Holland, G.N.; Hosea, S.; Silverberg, M.L. Herpes zoster ophthalmicus in an otherwise-healthy child. J. AAPOS 2005, 9, 597–598. [CrossRef]
13. Levin, M.J.; DeBlasi, R.L.; Bostik, V.; Schmid, D.S. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J. Infect. Dis. 2008, 198, 1444–1447. [CrossRef]
14. Obieta, M.P.; Jacinto, S.S. Herpes zoster after varicella vaccination in a healthy young child. Int. J. Dermatol. 2008, 47, 640–641. [CrossRef]
15. Ota, K.; Kim, V.; Lavi, S.; Ford-Jones, E.L.; Tipple, G.; Scolnik, D.; Tellier, R. Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old. Pediatr. Infect. Dis. J. 2008, 27, 847–848. [CrossRef]
16. Iyer, S.; Mittal, M.K.; Hodinka, R.L. Herpes zoster and meningitis resulting from reactivation of varicella virus in an immunocompetent child. Ann. Emerg. Med. 2009, 53, 792–795. [CrossRef]
17. Lin, P.; Yoon, M.K.; Chiu, C.S. Herpes zoster keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination. Ocul. Immunol. Inflamm. 2009, 17, 33–35. [CrossRef]
18. Chouliaras, G.; Spoulou, V.; Quinlivan, M.; Breuer, J.; Theodoridou, M. Vaccine-associated herpes zoster ophthalmicus [correction of ophthalmicus] and encephalitis in an immunocompetent child. Pediatrics 2010, 125, e969–e972. [CrossRef]
19. Han, J.Y.; Hanson, D.C.; Way, S.S. Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child. Pediatr. Infect. Dis. J. 2011, 30, 266–268. [CrossRef]
20. Esposito, S.; Bosis, S.; Pinzani, R.; Morlacchi, L.; Senatore, L.; Principi, N. A case of meningitis due to varicella zoster virus reactivation in an immunocompetent child. Ital. J. Pediatr. 2013, 39, 72. [CrossRef]
21. Ryu, W.Y.; Kim, N.Y.; Kwon, Y.H.; Ahn, H.B. Herpes zoster ophthalmicus with isolated trochlear nerve palsy in an otherwise healthy 13-year-old girl. *J. AAPOS* 2014, 18, 193–195. [CrossRef]  
22. Iwasaki, S.; Motokura, K.; Honda, Y.; Mikami, M.; Hata, D.; Hata, A. Vaccine-strain herpes zoster found in the trigeminal nerve area in a healthy child: A case report. *J. Clin. Virol.* 2016, 85, 44–47. [CrossRef]  
23. Peterson, N.; Goodman, S.; Peterson, M.; Peterson, W. Herpes zoster in children. *Cuttis* 2016, 98, 94–95.  
24. Dreyer, S.; Hemarajata, P.; Hogeling, M.; Henderson, G.P. Pediatric vaccine-strain herpes zoster: A case series. *Pediatr. Dermatol.* 2017, 34, 665–667. [CrossRef]  
25. Guffey, D.J.; Koch, S.B.; Bomar, L.; Huang, W.W. Herpes zoster following varicella vaccination in children. *Cuttis* 2017, 99, 207–211.  
26. Oliveira, K.; Fonseca, J.; Moreira, D.; Vila Real, M. Varicella-zoster virus meningitis in an immunocompetent paediatric patient. *Neurologia* 2018, 33, 623–624. [CrossRef]  
27. Ashi, A.; Ali, A.; Alzahrani, M.; Ali, J.; Albar, R. Herpes Zoster Eruption in an Otherwise Healthy Child: A Case Report. *Cureus* 2019, 11, e5194. [CrossRef]  
28. Harrington, W.E.; Mato, S.; Burroughs, L.; Carpenter, P.A.; Gershon, A.; Schmid, D.S.; Englund, J.A. Vaccine Oka Varicella Meningitis in Two Adolescents. *Pediatrics* 2019, 144, e20191522. [CrossRef]  
29. Moodley, A.; Swanson, J.; Grose, C.; Bonthius, D.J. Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children. *J. Child Neurol.* 2019, 34, 184–188. [CrossRef] [PubMed]  
30. Pelekouda, E.; Papagiannis, D.; Tsiaoussi, I.; Maltezou, H.C. Herpes zoster after vaccination with one dose varicella vaccine to a 4-year-old child. *Infec. Med.* 2019, 27, 449–451. [PubMed]  
31. Plachouri, K.M.; Gkentzi, D.; Varvarigou, A.; Georgiou, S.; Dimitriou, G. Herpes Zoster Onset 9 Years after First Varicella Zoster Vaccination in an 11-year-old Child—A Case Report. *Curr. Pediatr. Rev.* 2019, 15, 265–267. [CrossRef] [PubMed]  
32. Yasuda, R.; Minami, K.; Ogawa, A.; Okada, H.; Terakawa, R.; Koike, Y.; Ogura, S.; Takeuchi, K.; Higuchi, T. Herpes zoster and meningitis in an immunocompetent child: A case report. *J. Med. Case Rep.* 2019, 13, 182. [CrossRef]  
33. Quesada, D.; Morsky, L.; Aguiniga-Navarrete, P.; Garrett, M.B. Pediatric Herpes Zoster. *Clin. Pract. Cases Emerg. Med.* 2020, 4, 32–34. [CrossRef]  
34. Heusel, E.H.; Grose, C. Twelve Children with Varicella Vaccine Meningitis: Neuropathogenesis of Reactivated Live Attenuated Varicella Vaccine Virus. *Viruses* 2020, 12, 1078. [CrossRef]  
35. Kangro, H.O.; Ward, A.; Argent, S.; Heath, R.B.; Cradock-Watson, J.E.; Ridehalgh, M.K. Detection of specific IgM in varicella and herpes zoster by antibody-capture radioimmunoassay. *Epidemiol. Infect.* 1988, 101, 187–195. [CrossRef]  
36. Min, S.W.; Kim, Y.S.; Nahm, F.S.; Yoo, D.H.; Choi, E.; Lee, P.B.; Choo, H.; Park, Z.Y.; Yang, C.S. The positive duration of varicella zoster immunoglobulin M antibody test in herpes zoster. *Medicine* 2016, 95, e4616. [CrossRef]  
37. Körholz, J.; Richter, N.; Schäfer, J.; Schuetz, C.; Roessler, J. A case of recurrent herpes simplex 2 encephalitis, VZV reactivations, and dominant partial interferon-gamma-receptor-1 deficiency supports relevance of IFNgamma for antiviral defense in humans. *Mol. Cell Pediatr.* 2020, 7, 14. [CrossRef]  
38. Dorman, S.E.; Picard, C.; Lammas, D.; Heyne, K.; van Dissel, J.T.; Baretto, R.; Rosenzweig, S.D.; Newport, M.; Levin, M.; Roessler, J.; et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. *Lancet* 2004, 364, 2113–2121. [CrossRef]